# A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

> **NCT06935370** · PHASE3 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 4200 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** vicadrostat
- **DRUG:** empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06935370
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-20
- **Primary completion:** 2029-02-04
- **Final completion:** 2029-02-22
- **Target enrollment:** 4200 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06935370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06935370, "A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT06935370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*